Human platelet lysates (HPL), isolated from human mesenchymal stem cells, are serving an excellent alternative to fetal bovine serum (FBS). The replacement of FBS helps in the prevention of bovine prion and viral contamination, and can also represent a new therapeutic challenge in the field of stem cell therapy, increasing the demand of human platelet lysates.
The evolution of human platelet lysates has boosted various experimental and clinical research studies. Human platelet lysates do not affect functional capacities. Alternatives to FBS are human blood-derived components, namely, plasma, serum, umbilical cord blood serum, and platelet derivatives such as platelet lysates.
Multiple applications of human platelet lysates, such as research, development, and production of biotechnology and pharmaceutical drug breakthrough therapies, is expected to increase the growth of human platelet lysate market.
Find Out More about the Report Coverage
- Merck KGaA
- Compass Biomedical Inc.
- Macopharma SA
- Mill Creek Life Sciences Llc.
- Stemcell Technologies Inc.
- Zen-Bio, Inc.
- Sclavo Diagnostics International Srl.
- Life Science Group Limited (Life Science Production)
- Trinova Biochem Gmbh
Increasing Government Funding to Boost Human Platelet Lysate Market Growth
Increasing government funding for life science-related projects, and rising number of research centers and research institutes, are factors driving the growth of the human platelet lysate market.
In 2013, around 59% of total research & development expenditure in the U.S. was from federal funding agencies. In 2016, 12% of federal stem cell research funding was allocated to human embryonic stem cell research.
Customize this Report
Explore Intelligence Tailored to Your Business Goals.
Collaboration - Strategic Focus for Lucrative Growth Opportunities
To maximize research output, research institutes and biotech companies are collaborating for clinical trials and other research projects. Cambium Medical Technologies LLC collaborated with Massachusetts Eye and Ear Infirmary, Oregon Health and Science University, University of Michigan, and Duke University for a clinical trial of topical fibrinogen-depleted human platelet lysates in patients with dry eye secondary to graft vs. host disease.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
Increasing Demand for Biopharmaceuticals to Propel Human Platelet Lysate Market
With increasing incidence of several virus- or bacteria-borne infections and diseases, the scope of biopharmaceuticals is also increasing. Monoclonal antibody (MAb) therapeutics is amongst the most dynamic and promising pipelines in the biopharmaceutical market.
Above 200 biopharmaceutical products are marketed and many more are in the development phase. Various biopharmaceutical products such as cancer vaccines, RNA interference, stem cells, cultured tissue transplants, and genes are going to be great assets for public health over the coming years.
Explore Persistence Market Research’s expertise in promulgation of the business !
A comprehensive perspective of the human platelet lysate market has led our analysts to infer that, the market is growing at a decent rate, with North America, followed by Europe, holding a large share in the global human platelet lysate market, attributable to well-developed research centers in these regions.
Increasing research & developmental activities have led to the adoption of human platelet lysates in developed countries of North America and Europe. New product launches are anticipated to create more opportunities for players in the global human platelet lysate market.
Key Segments of Human platelet lysate Market
PMR’s study on the human platelet lysate market offers information divided into four important segments - product type, application, end user, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Key Questions Answered in Report
- How much is the human platelet lysate market worth?
The global human platelet lysate market will reach US$ 70 Mn by the year 2031.
- What will be the demand outlook?
The global human platelet lysate market will witness steadiness in the form of CAGR of 4% between 2021 and 2031.
- What was the last 5 year market CAGR?
The human platelet lysate market witnessed a CAGR of 3.5% between 2015 and 2020.
- What are the key trends for the human platelet lysate market?
The ongoing trends imply prevalence of heparin-free as well as heparin-included platelet lysates, thanks to clinical application of the same.
- What is driving the demand forhuman platelet lysates?
Developing economies vying for human platelet lysates – thanks to increasing awareness – is the factor driving the human platelet lysate market.
- What is the market share of top 5 players?
The top 5 players hold more than 80% of the market. They are inclusive of Compass Biomedical Inc., Merck KGaA, Macopharma SA, Cook Medical, and Mill Creek Life Sciences LLC.
- What are the top 5 countries driving demand?
The top 5 countries driving demand include the US, UK, Australia, China, and India.
- What is the North America’s market Outlook?
North America holds a stupendous growth rate with the US calling the shots.
- At what percentage human platelet lysate market is going to register growth in Europe?
Europe will register growth at the rate of 3% in the human platelet lysate market between 2021 and 2031.
- What is the key market statistics in Korea and Japan?
Japan and Korea will come to terms with growth in human platelet lysate market in the years to come.